Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448820 | 0.88 | MAPT (0.38) | NR3C2MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL23707743 | 0.78 | NOTUM (0.34) | NR3C2KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL17026884 | 0.78 | NOTUM (0.34) | NR3C2KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL17026861 | 0.76 | TRPV1 (0.37) | NR3C2KDM4EALDH1A1NOTUMLMNA | |
| SCHEMBL755634 | 0.76 | NR3C2 (0.63) | NR3C2MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL17175213 | 0.75 | NISCH (0.52) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL9142188 | 0.74 | NR3C2 (0.35) | NR3C2MEN1KMT2AADRA2AADRA2B | |
| SCHEMBL430404 | 0.72 | ALDH1A1 (0.44) | MAPTKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL28875503 | 0.72 | MAPT (0.39) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL24359289 | 0.71 | NR3C2 (0.40) | NR3C2ALDH1A1F2NISCHL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| EP-1368357-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002068427-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | NR3C2 21/4885MAPT 2518/4885KDM4E 2013/4885 |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | NR3C2 16/4885MAPT 2588/4885KDM4E 2243/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | NR3C2 16/4885MAPT 2588/4885KDM4E 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.